TY - JOUR
T1 - Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E
AU - Hatheway, Charles H.
AU - Snyder, John D.
AU - Seals, Jerry E.
AU - Edell, Timm A.
AU - Lewis, George E.
PY - 1984
Y1 - 1984
N2 - Serum levels of equine-botulism antitoxin to toxin types A, B, and E were measured in four type-A botulism patients who had received equine-botulism antitoxin. High circulating levels capable of neutralizing in excess of 1 x 108, 9 x 107, and 6 x 106 50% mouse lethal doses of toxin of types A, B, and E, respectively, were detected. There was little depletion of type-A antitoxin even though two of the patients had circulating type-A toxin before treatment. The half-life for antitoxin persistence for one patient was calculated as being 6.5, 7.6, and 5.3 days for antitoxin types A, B, and E, respectively. Antitoxin levels were not proportionate to the amount (range, 2-4 vials) injected and did not appear to be affected by whether the route of administration was iv or im. Peak serum levels of antitoxin were 10-1,000 times higher than amounts needed to neutralize the toxin measured in the serum of these and other patients with botulism.
AB - Serum levels of equine-botulism antitoxin to toxin types A, B, and E were measured in four type-A botulism patients who had received equine-botulism antitoxin. High circulating levels capable of neutralizing in excess of 1 x 108, 9 x 107, and 6 x 106 50% mouse lethal doses of toxin of types A, B, and E, respectively, were detected. There was little depletion of type-A antitoxin even though two of the patients had circulating type-A toxin before treatment. The half-life for antitoxin persistence for one patient was calculated as being 6.5, 7.6, and 5.3 days for antitoxin types A, B, and E, respectively. Antitoxin levels were not proportionate to the amount (range, 2-4 vials) injected and did not appear to be affected by whether the route of administration was iv or im. Peak serum levels of antitoxin were 10-1,000 times higher than amounts needed to neutralize the toxin measured in the serum of these and other patients with botulism.
UR - http://www.scopus.com/inward/record.url?scp=0021176226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021176226&partnerID=8YFLogxK
U2 - 10.1093/infdis/150.3.407
DO - 10.1093/infdis/150.3.407
M3 - Article
C2 - 6481185
AN - SCOPUS:0021176226
VL - 150
SP - 407
EP - 412
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 3
ER -